IQVIA (NYSE:IQV – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday.
Several other brokerages have also commented on IQV. The Goldman Sachs Group decreased their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Truist Financial reduced their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Robert W. Baird reduced their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Finally, Morgan Stanley cut their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.
View Our Latest Analysis on IQV
IQVIA Stock Up 1.6 %
Insider Buying and Selling
In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by company insiders.
Institutional Trading of IQVIA
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Unigestion Holding SA purchased a new stake in IQVIA in the third quarter valued at $521,000. TD Private Client Wealth LLC boosted its stake in shares of IQVIA by 8.4% in the third quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock worth $244,000 after buying an additional 80 shares during the last quarter. Toronto Dominion Bank grew its holdings in IQVIA by 11.3% during the third quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock worth $14,317,000 after acquiring an additional 6,149 shares during the period. Neo Ivy Capital Management acquired a new position in IQVIA in the third quarter valued at approximately $470,000. Finally, Brown Financial Advisors boosted its position in IQVIA by 13.0% in the 3rd quarter. Brown Financial Advisors now owns 3,432 shares of the medical research company’s stock worth $813,000 after purchasing an additional 396 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
- Five stocks we like better than IQVIA
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.